TY - JOUR AU - Henrique Aragao, Afonso AU - Sanabria Duarte, Joel AU - Benzecry Almeida, Daniel AU - Ramina, Ricardo PY - 2020/09/30 Y2 - 2024/03/28 TI - CGRP: from history to clinical application - A review JF - Headache Medicine JA - Headache Med VL - 11 IS - 3 SE - Review DO - 10.48208/HeadacheMed.2020.18 UR - https://headachemedicine.com.br/index.php/hm/article/view/304 SP - 61-67 AB - <p>The role of calcitonin gene-related peptide (CGRP) and its receptor have played an important role in migraine for the last decades due to development of therapies that target their receptors at the trigeminal pain system, aiming at prevention or relief of acute migraine attacks. At first, CGRP&nbsp;receptor antagonists, called gepants have demonstrated appropriate effectiveness. In addition, they did not cause vasoconstriction, one of the drawbacks of triptans. However, their use had to be discontinued due to the risk of liver toxicity. Humanized monoclonal antibodies towards&nbsp;CGRP&nbsp;and the&nbsp;CGRP&nbsp;receptor have been developed as an alternative approach to block&nbsp;CGRP&nbsp;transmission. Still, there are some questions not fully answered as where CGRP and its receptor are located, how they influence the mechanisms of migraine attacks and if the blood brain barrier has any sort of importance. There is still much to learn about CGRP and migraine pathophysiology, especially its anatomical target sites and anti-CGRP agents. This paper presents a review of CGRP, including a brief history, focusing in CGRP mechanism, updates and future treatments.</p> ER -